




RealRate

PHARMACEUTICAL 2022

Verona Pharma plc
Rank 178 of 471



Verona Pharma
Breath of Innovation



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Verona Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verona Pharma plc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 43% points. The greatest weakness of Verona Pharma plc is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 52% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	170,063
Cost of Goods Sold	0
Intangible Assets	545
Liabilities, Current	33,422
Liabilities, Non-Current	5,160
Other Assets	15,899
Other Compr. Net Income	0
Other Expenses	-18
Other Liabilities	0
Other Net Income	17,726
Other Revenues	40,000
Property and Equipment	80
Research and Development	79,406
Selling, General and Administrative Expense	33,907

Output Variable	Value in 1000 USD
Assets	186,587
Liabilities	38,582
Expenses	113,295
Revenues	40,000
Stockholders Equity	148,005
Net Income	-55,569
Comprehensive Net Income	-55,569
BaseVar	198,095
ECR before LimitedLiability	237%
Economic Capital Ratio	327%